Fu-Lian Qu, Yao-Hong Gao, Yan Zhang, Hong-Rui Zhang, Ya-Zhen Hong, Xiao-Jing Tie, Pei-Jie Liu
{"title":"Comparative analysis of antiangiogenic and immunotherapeutic regimens in the treatment of metastatic pulmonary lymphoepithelioma-like carcinoma.","authors":"Fu-Lian Qu, Yao-Hong Gao, Yan Zhang, Hong-Rui Zhang, Ya-Zhen Hong, Xiao-Jing Tie, Pei-Jie Liu","doi":"10.1186/s13019-025-03534-3","DOIUrl":"10.1186/s13019-025-03534-3","url":null,"abstract":"<p><strong>Background and objective: </strong>Pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare histological subtype of non-small cell lung cancer for which no standard treatment protocol exists in the metastatic setting. This study aims to evaluate the efficacy and safety of antiangiogenic agents and immune checkpoint inhibitors (ICIs), individually and in combination with cytotoxic chemotherapy, in patients diagnosed with metastatic PLELC. The findings aim to inform therapeutic strategies for this uncommon malignancy.</p><p><strong>Method: </strong>A retrospective analysis of electronic medical records was performed to identify patients diagnosed with metastatic PLELC. Based on the treatment regimens received, participants were stratified into three groups: antiangiogenic agents plus ICIs (AI group), antiangiogenic agents plus ICIs and cytotoxic chemotherapy (AIC group), and antiangiogenic agents plus cytotoxic chemotherapy without ICIs (AC group).</p><p><strong>Results: </strong>Nineteen patients were included in the analysis. The overall objective response rate (ORR) was 78.9% (15/19), the disease control rate (DCR) was 94.8% (18/19), and the median progression-free survival (mPFS) was 12.9 months. In the AIC group, the ORR was 72.7% (8/11), the DCR was 90.9% (10/11), and the mPFS was 16.0 months. In the AI group, the ORR was 83.3% (5/6), the DCR was 100% (6/6), and the mPFS was 12.35 months. In the AC group, both the ORR and DCR were 100% (2/2), with an mPFS of 6.45 months. Patients in the AIC group exhibited substantial tumor regression. Furthermore, those with programmed death-ligand 1 (PD-L1) expression ≥ 50% experienced significantly prolonged mPFS compared to patients with PD-L1 expression < 50%. Following disease progression, clinical conditions remained stable under subsequent antiangiogenic therapy.</p><p><strong>Conclusion: </strong>The combination of antiangiogenic agents, ICIs, and cytotoxic chemotherapy demonstrated promising efficacy and an acceptable safety profile in the treatment of metastatic PLELC. These findings support further exploration of multi-modality regimens in this rare lung cancer subtype.</p>","PeriodicalId":15201,"journal":{"name":"Journal of Cardiothoracic Surgery","volume":"20 1","pages":"302"},"PeriodicalIF":1.5,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12265251/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144649583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Primary cardiac diffuse large B-cell lymphoma patient: clinical, histologic, immunophenotypic feature and a novel surgical technology: a case report.","authors":"Chenxi Ying, Weidong Li, Yu Zou, Bohao Dai, Xin Chen","doi":"10.1186/s13019-025-03532-5","DOIUrl":"10.1186/s13019-025-03532-5","url":null,"abstract":"<p><strong>Background: </strong>Primary cardiac lymphoma (PCL) is a rare malignancy, representing a small fraction of primary cardiac tumors. Non-germinal center B-cell (non-GCB) diffuse large B-cell lymphoma (DLBCL), a subtype of PCL, often presents with severe symptoms due to its cardiac involvement, and poses diagnostic and therapeutic challenges. This case highlights the use of an innovative surgical approach in managing a non-GCB primary cardiac DLBCL.</p><p><strong>Case presentation: </strong>We report the case of a 68-year-old woman presenting with palpitations, dizziness, and obstructive cardiac symptoms. Diagnostic imaging revealed a large mass in the right atrium near the superior vena cava. A novel \"zongzi\"-shaped endoscopic gauze folding technique was employed to facilitate complete tumor resection while preserving cardiac structure. Pathology confirmed double expressor DLBCL with BCL2 and MYC co-expression, indicating a high-risk profile. The patient's postoperative course was uneventful, and she was discharged in stable condition. However, follow-up imaging at six months revealed local disease progression.</p><p><strong>Conclusions: </strong>This case underscores the challenges in managing primary cardiac DLBCL and highlights the potential of novel surgical techniques to improve resection outcomes while minimizing structural damage to the heart. Further research is essential to optimize multimodal approaches, particularly for aggressive PCL subtypes like double expressor lymphoma.</p>","PeriodicalId":15201,"journal":{"name":"Journal of Cardiothoracic Surgery","volume":"20 1","pages":"304"},"PeriodicalIF":1.5,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12265133/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144649587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aleena Ihtasham, Sahla Waqas, Muhammad Hamza, Haider Imran, Saraiba Sabar Chaudhary, Tayyaba Qayyum, Sadia Batool, Nimarta Devi, Muhammad Ali Muzammil, Malik Olatunde Oduoye
{"title":"Innovative strategies in coagulation management for cardiothoracic surgery: a narrative review of pharmacological and nonpharmacological approaches.","authors":"Aleena Ihtasham, Sahla Waqas, Muhammad Hamza, Haider Imran, Saraiba Sabar Chaudhary, Tayyaba Qayyum, Sadia Batool, Nimarta Devi, Muhammad Ali Muzammil, Malik Olatunde Oduoye","doi":"10.1186/s13019-025-03406-w","DOIUrl":"10.1186/s13019-025-03406-w","url":null,"abstract":"<p><p>The challenging management of coagulation in cardiothoracic surgery requires a multifaceted approach. The use of pharmacological interventions such as tranexamic acid, heparin, and aprotinin minimizes bleeding but increases the associated risks of renal impairment and seizures. However, aprotinin has been replaced by tranexamic acid for safety reasons. Supplementing nonpharmacological techniques, such as hemostatic agents and mechanical devices, with these pharmacological strategies can enhance surgical coagulation management. During cardiopulmonary bypass, factors such as hypothermia, acidosis, and fibrinolysis worsen coagulation disturbances, and protamine sulfate is administered for heparin reversal during the procedure. Point-of-care devices, including thromboelastography (TEG®) and rotational thromboelastometry (ROTEM®), provide real-time monitoring of coagulation, hence guiding clinical interventions effectively, and have demonstrated a reduction in postoperative bleeding. Nonetheless, tailored approaches are critical, especially in patients with preexisting coagulation disorders as well as in pediatric surgery. Pharmacogenomics also plays a role in selecting appropriate dosages and minimizing adverse outcomes. Recent advancements in this context include novel hemostatic agents, prothrombin complex concentrates, and direct oral anticoagulants. Future research should not only explore the combined use of pharmacological and nonpharmacological strategies but also evaluate the long-term effects and cost-effectiveness of integrated approaches during cardiothoracic surgery, particularly in high-risk populations.</p>","PeriodicalId":15201,"journal":{"name":"Journal of Cardiothoracic Surgery","volume":"20 1","pages":"305"},"PeriodicalIF":1.5,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12269227/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144649585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Qiaoling Ying, Hui Xu, Xiaojiao Wu, Hang Fang, Jingjing Shi, Hangcheng Pan
{"title":"Clinical significance of lncRNA PAX8-AS1 and miR-96-5p in non-small cell lung cancer.","authors":"Qiaoling Ying, Hui Xu, Xiaojiao Wu, Hang Fang, Jingjing Shi, Hangcheng Pan","doi":"10.1186/s13019-025-03542-3","DOIUrl":"10.1186/s13019-025-03542-3","url":null,"abstract":"<p><strong>Background: </strong>This study aims to examine the potential value of lncRNA PAX8-AS1 and miR-96-5p as diagnostic markers in non-small cell lung cancer (NSCLC). The goal is to provide a reference for improving adverse outcomes in NSCLC and developing effective early interventions in the clinic.</p><p><strong>Methods: </strong>A total of 112 NSCLC patients and 70 healthy volunteers were recruited as the study subjects. The expression levels of PAX8-AS1 and miR-96-5p were measured using fluorescence quantitative PCR. The expression levels of PAX8-AS1 and miR-96-5p were detected by fluorescence quantitative PCR. A dual luciferase reporter assay was used to detect the binding of PAX8-AS1 and miR-96-5p. ROC, Kaplan-Meier, and Cox regression analysis was used to assess the diagnostic and prognostic value of PAX8-AS1 and miR-96-5p in NSCLC.</p><p><strong>Results: </strong>In NSCLC, PAX8-AS1 was found to be downregulated, whereas miR-96-5p was upregulated. These two molecules exhibited a negative correlation and a target-binding relationship. Receiver operating characteristic (ROC) curve analysis demonstrated that PAX8-AS1 and miR-96-5p had practical diagnostic values for distinguishing NSCLC patients. Mortality increased in NSCLC patients with low PAX8-AS1 levels and decreased in those with low miR-96-5p levels. Cox regression analysis showed that PAX8-AS1 and miR-96-5p could serve as independent predictors of prognostic survival in NSCLC patients.</p><p><strong>Conclusion: </strong>PAX8-AS1 and miR-96-5p can serve as potential diagnostic biomarkers for NSCLC patients.</p>","PeriodicalId":15201,"journal":{"name":"Journal of Cardiothoracic Surgery","volume":"20 1","pages":"299"},"PeriodicalIF":1.5,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12257718/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144637119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Nicorandil in improving angina pectoris and vascular endothelial function in elderly diabetes mellitus patients with coronary heart disease.","authors":"Ling Gao","doi":"10.1186/s13019-025-03449-z","DOIUrl":"10.1186/s13019-025-03449-z","url":null,"abstract":"<p><strong>Objective: </strong>To explore the clinical efficacy of nicorandil in treating elderly angina pectoris with diabetes mellitus (DM) and coronary heart disease (CHD), and the effect on improving vascular endothelial function (VEF).</p><p><strong>Methods: </strong>110 elderly diabetic patients with CHD and angina pectoris who were treated in our hospital from April 2019 to March 2022 were chose as samples. All the subjects were distributed into 2 groups, namely A and B, and 55 people in each. B group were treated with secondary preventive drugs for CHD, and the A group were treated with nicorandil and secondary preventive drugs for CHD. After one month, the clinical efficacy, prethrombotic state, VEF, inflammatory factor levels, cardiac function were compared.</p><p><strong>Results: </strong>The bg, DD, PAI-1, vWF, ET-1, TNF-α and hs-CRP in A group after the treatment were below those in B (P < 0.05), t-PA, FMD, The NO content was significantly exceeded that of the B group. The LVEF and RHI indexes in A were exceed the data in B (P < 0.05), and the LVEDD and LVPWd were below the data in B (P < 0.05). The effective rate of clinical treatment in A was significantly exceed B's data.</p><p><strong>Conclusion: </strong>Nicorandil can significantly improve angina pectoris in elderly patients with DM and CHD.</p>","PeriodicalId":15201,"journal":{"name":"Journal of Cardiothoracic Surgery","volume":"20 1","pages":"295"},"PeriodicalIF":1.5,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12257808/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144626407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Long non-coding RNA SNHG16 promotes tumor progression and cisplatin resistance in esophageal squamous cell carcinoma via miR-497-5p/HK2 axis.","authors":"Xiaofeng Zhu, Minghua Xie, Yayun Cui","doi":"10.1186/s13019-025-03528-1","DOIUrl":"10.1186/s13019-025-03528-1","url":null,"abstract":"<p><strong>Background: </strong>Esophageal squamous cell carcinoma (ESCC) is a prevalent gastrointestinal malignancy characterized by a high incidence and mortality rate. ESCC frequently develops drug resistance during chemotherapy, resulting in diminished clinical efficacy. Previous studies have identified SNHG16, a long non-coding RNA, as a crucial oncogene, but its underlying mechanisms in the biological functions and chemoresistance regulation in ESCC remain unclear.</p><p><strong>Methods: </strong>RT-qPCR and western blotting were utilized to detect SNHG16, miR-497-5p, and HK2 expression in DDP-resistant/sensitive ESCC tissues and cells. In vitro functional experiments were performed by transfecting DDP-resistant ESCC cells lines with sh-SNHG16, including CCK8, flow cytometry, EdU assay, and transwell assay. Mechanistically, the mechanistic aspects and target binding relationship were established through the luciferase reporter assay. In vivo xenograft model was established to examine the impact of SNHG16.</p><p><strong>Results: </strong>SNHG16 was significantly overexpressed in both DDP-resistant ESCC tissues and cells. Functional in vitro studies demonstrated that silencing SNHG16 significantly inhibited the proliferation, migration and invasion of ESCC cells, induced cell apoptosis, and sensitized DDP-resistant cells to DDP. Moreover, SNHG16 exerted malignant biological behavior in ESCC cells and conferred cisplatin resistance by acting as a sponge for miR-497-5p and regulating HK2.</p><p><strong>Conclusions: </strong>Our findings uncovered that SNHG16 promoted ESCC malignant progression and DDP resistance through the miR-497-5p/HK2 axis, laying the groundwork for deciphering the molecular mechanisms underlying chemotherapy resistance in ESCC and developing new treatment strategies.</p>","PeriodicalId":15201,"journal":{"name":"Journal of Cardiothoracic Surgery","volume":"20 1","pages":"298"},"PeriodicalIF":1.5,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12257804/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144637128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kai Xiong, Hao Fang, Caihong Song, Dilihumaer Tuerxun, Peng Zhang
{"title":"Identification of potential drug targets for achalasia from genetic insights: a Mendelian randomization study.","authors":"Kai Xiong, Hao Fang, Caihong Song, Dilihumaer Tuerxun, Peng Zhang","doi":"10.1186/s13019-025-03538-z","DOIUrl":"10.1186/s13019-025-03538-z","url":null,"abstract":"<p><strong>Background: </strong>Achalasia (AC) is an esophageal dyskinetic disorder characterized by loss of function of ganglion cells of the intermuscular plexus of the distal esophagus and lower esophageal sphincter. Although there have been some advances in its diagnosis and treatment, the maintenance of pharmacologic therapy is very short-lived, the indications for surgical treatment are more limited, and postoperative complications have not been resolved. Therefore, targeted prediction of drugs for better treatment of AC is of great clinical interest.</p><p><strong>Methods: </strong>In this study, we utilized a large number of drug-related databases to perform Mendelian randomization (MR) analysis and co-localization analysis of the data from the genome-wide association study (GWAS) of blood expression quantitative trait loci (eQTL) and AC, so as to identify genes that are highly associated with AC, and screened them in combination with differential genes analyzed by transcriptome sequencing data. In addition, phenotype-wide studies, enrichment analysis, protein network construction, drug prediction, and molecular docking were performed to provide valuable guidance for the development of more effective and targeted therapeutic drugs.</p><p><strong>Results: </strong>We identified nine potential drug target genes for the treatment of AC (NOG, FGFBP3, BST2, IFIT1, CD28, QPCT, IGSF11 and CDK14), which are differentially expressed in AC with different subtypes and sites. These genes were predominantly enriched in virus-associated pathways. The optimal genes for distal esophagus of type 1 AC, distal esophagus of type 2 AC, proximal esophagus of type 1 AC and proximal esophagus of type 2 AC were BST2, FGFBP3, NOG and CDK14, respectively, and our predicted most likely effective potential drugs were puromycin, pictilisib, chlorpyrifos oxon, R547.</p><p><strong>Conclusion: </strong>This study identifies potential drug targets for the treatment of different fractions and sites of AC, and these findings provide promising clues for more effective treatment of AC and have the potential to reduce drug development costs.</p>","PeriodicalId":15201,"journal":{"name":"Journal of Cardiothoracic Surgery","volume":"20 1","pages":"296"},"PeriodicalIF":1.5,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12257857/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144626406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Identification and analysis of pyroptosis-related key genes in heart failure.","authors":"Jing Zhang, Zhijie Yue, Na Zhu, Na Zhao","doi":"10.1186/s13019-025-03530-7","DOIUrl":"10.1186/s13019-025-03530-7","url":null,"abstract":"<p><strong>Background: </strong>Pyroptosis plays a pivotal role in the pathogenesis of Heart Failure (HF). However, the current understanding of how pyroptosis-related genes (PRGs) influence HF is scarce. This study aimed to explore the link between PRGs and HF based on bioinformatics.</p><p><strong>Methods: </strong>Three datasets of HF were involved in this study.Candidate genes were identified by overlapping two sets of genes. The first set consisted of differentially expressed genes from differential expression analysis. The second set included critical module genes from weighted gene co-expression network analysis. Further, the key genes were screened based on machine learning algorithms. Furthermore, immune infiltration analysis and mRNA-Transcription factor (TF)/drug regulatory networks construction were implemented. Ultimately, we also verified the expression of key genes.</p><p><strong>Results: </strong>In this study, we pinpointed seven key genes (SNORD76, RPS3A, SNORD1A, CCDC159, AMT, RANBP6, and CRAT) exhibiting superior diagnostic potential in HF. We found five distinct immune cell types to be significantly associated with these key genes. Moreover, CRAT and AMT were subject to regulation by PHF8. Additionally, AMT, RPS3A, and CRAT corresponded to eight potential therapeutic drugs. Importantly, the expression of CCDC159, CRAT, and AMT was consistent with the dataset.</p><p><strong>Conclusion: </strong>We identified the seven key genes that were intimately associated with HF, offering novel insights into the therapeutic targets for HF.</p>","PeriodicalId":15201,"journal":{"name":"Journal of Cardiothoracic Surgery","volume":"20 1","pages":"300"},"PeriodicalIF":1.5,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12257851/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144637121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Elevated tumour markers in the pleural effusion of a patient with spontaneous esophageal rupture: a rare case report.","authors":"Huaimin Liang, Xiaoning Li, Zhengliang Wei","doi":"10.1186/s13019-025-03539-y","DOIUrl":"10.1186/s13019-025-03539-y","url":null,"abstract":"<p><strong>Background: </strong>Esophageal rupture is a rare but life-threatening condition. Esophageal tumours do not usually cause esophageal ruptures, and elevated tumour markers have rarely been detected in pleural effusion after esophageal rupture with no detectable tumour. The presence of elevated tumor markers in pleural effusion can lead to a misdiagnosis of esophageal cancer in patients with esophageal rupture, resulting in inappropriate treatment.</p><p><strong>Case presentation: </strong>The 65-year-old male patient who was admitted to the emergency department with left chest pain and dyspnoea after severe vomiting. Chest computed tomography (CT) indicated left hydropneumothorax and mediastinal emphysema. The patient underwent bedside closed thoracic drainage. The drainage fluid was coffee-coloured and turbid, with significantly elevated CA199, CA125 and CEA levels. After transferring the patient to the emergency operating room, the esophageal defect was repaired, and a jejunostomy was performed. No tumours were detected in the thoracic cavity during surgery. The patient recovered and was discharged from the hospital.</p><p><strong>Conclusion: </strong>Esophageal tumours should be suspected in patients with elevated pleural effusion CA199, CA125 and CEA levels. The findings from chest CT and oesophagography did not support the diagnosis of a thoracic tumor.These tumor markers may be concomitant changes during esophageal rupture.</p>","PeriodicalId":15201,"journal":{"name":"Journal of Cardiothoracic Surgery","volume":"20 1","pages":"301"},"PeriodicalIF":1.5,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12257646/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144637120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The role of thoracic surgeons in spinal surgery: our clinical experiences.","authors":"Kadir Baturhan Ciflik, Busra Ozdemir Ciflik, Yucel Akkas, Suleyman Anil Akboga, Anil Gokce, Ercan Bal, Mehmet Atif Erol Aksekili, Bulent Kocer","doi":"10.1186/s13019-025-03537-0","DOIUrl":"10.1186/s13019-025-03537-0","url":null,"abstract":"<p><strong>Objective: </strong>In the thoracic area, the outside edge of the vertebrae exhibits intricate anatomical features. A multidisciplinary approach is necessary, particularly in scoliosis surgery, while performing manipulations on the vertebra from the front. Our objective in this study was to enhance the existing body of knowledge by sharing our firsthand experience in the field of spinal surgery.</p><p><strong>Methods: </strong>We have seen a total of 35 cases in our investigation. When doing vertebral body tethering (VBT) in chosen scoliosis patients, thoracoscopy and thoracotomy have been the favored methods. On the other hand, alternative circumstances have favored the usual thoracotomy method.</p><p><strong>Results: </strong>We operated on three (8.6%) patients for trauma, six (17.1%) for mass, and 26 (74.2%) for scoliosis. Twenty (57.1%) of the patients operated for scoliosis underwent VBT. In patients undergoing VBT, a greater number of vertebrae were accessed thoracoscopy compared to thoracotomy (p = 0.003). There was no significant difference between the two groups in terms of chest tube follow-up time, length of stay in the intensive care unit, and hospital stay (p = 0.451, p = 0.403, p = 0.125).</p><p><strong>Conclusion: </strong>Our investigation demonstrated that the thoracoscopy is capable of intervening with a greater number of vertebrae compared to thoracotomy. Thoracic surgeons primarily focus their research on masses and trauma related to spinal surgery. Our study's large patient population with scoliosis surgery adds to the existing body of knowledge in the field of thoracic surgery. This study is significant as it is the second in the existing literature to document the experiences of thoracic surgeons from Turkey use of VBT.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":15201,"journal":{"name":"Journal of Cardiothoracic Surgery","volume":"20 1","pages":"297"},"PeriodicalIF":1.5,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12257691/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144626408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}